Clinical trials: Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Phase 1 Study of QX-4533 in Healthy Volunteers and Patients With Moderate-to-Severe Atopic Dermatitis
The goal of this clinical trial is to evaluate the safety and tolerability of QX-453, an investigational treatment, in healthy Chinese volunteers and patients with moderate-to-severe atopic dermatitis.
- Trial name
- NCT07800104
- Testing
- QX4533
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- QuantX Biosciences, Inc.
Atopic Dermatitis
Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis
This is an open-label, safety study designed to assess the multiple-dose pharmacokinetics and potential for adrenal suppression following topical treatment with halobetasol propionate 0.05% spray applied twice-daily in adult…
- Trial name
- NCT03245385
- Testing
- Treatment with Halobetasol propionate 0.05% topical spray
- Where
- 13 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Children and Adolescents With Moderate-to-severe Atopic Dermatitis
A Phase Ib/II Study to Investigate the Safety of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis
This trial was designed to evaluate the safety of SHR-1819 in children and adolescents with moderate-to-severe atopic dermatitis.
- Trial name
- NCT06713499
- Testing
- SHR-1819 injection
- Where
- 2 sites in China
- Volunteers
- 51 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Food Allergy
Effectiveness of Dupilumab in Food Allergic Patients With Moderate to Severe Atopic Dermatitis
This study evaluates the effectiveness of Dupilumab in food allergic patients with moderate to severe Atopic Dermatitis (AD). Included patients participated in the BioDay Registry.
- Trial name
- NCT04462055
- Where
- Netherlands
- Volunteers
- 3 people
- Sponsor
- UMC Utrecht
Dermatitis, Atopic
Evaluation of 611 in Chinese Adult Patients With Moderate-to-Severe Atopic Dermatitis
The primary objective of the study was to evaluate the safety and tolerability of 611 in chinese adults with moderate to severe atopic dermatitis.
- Trial name
- NCT05641558
- Testing
- 611 150mg, 611 300mg, 611 600mg
- Where
- 5 sites in China
- Volunteers
- 24 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Atopic Dermatitis
A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis
Participants who meet eligibility criteria will be randomized in a 1:1:1 ratio to receive a twice daily oral LNK01001 dose A or LNK01001 dose B or matching placebo for 12 weeks.
- Trial name
- NCT06085521
- Testing
- LNK01001 Dose A, LNK01001 Dose B
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Lynk Pharmaceuticals Co., Ltd
Atopic Dermatitis
A Study of Barzolvolimab in Patients With Atopic Dermatitis
The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with Atopic Dermatitis
- Trial name
- NCT06727552
- Testing
- Barzolvolimab
- Where
- 33 sites in United States
- Volunteers
- 131 people
- Sponsor
- Celldex Therapeutics
Dermatitis, Atopic
Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.
The study is designed to evaluate the long-term safety and efficacy of GSK1070806 in participants with moderate-to severe atopic dermatitis, who have completed phase 2b parent GSK atopic dermatitis (AtD) study (NCT05999799).
- Trial name
- AtDvance (NCT06447506)
- Testing
- GSK1070806
- Where
- 51 sites in United States, Argentina and 13 more
- Volunteers
- 79 people
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis
The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis
This study aims to assess the impact of dupilumab on the mental health and quality of life of moderate-to-severe Atopic Dermatitis (AD) patients.
- Trial name
- DERMIND-AD (NCT07467564)
- Testing
- Dupilumab
- Where
- 7 sites in Qatar, Saudi Arabia and 1 more
- Volunteers
- 184 people
- Sponsor
- Sanofi
Atopic Dermatitis, Atopic
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.
- Conditions
- Atopic Dermatitis, Atopic, Dermatitis, AD
- Trial name
- NCT07011706
- Testing
- ATI-045
- Where
- 60 sites in United States, Canada
- Volunteers
- 110 people
- Sponsor
- Aclaris Therapeutics, Inc.
Atopic Dermatitis (AD)
Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis
The goal of this clinical trial is to learn about the safety and tolerability of ENV-294 in adults with moderate to severe atopic dermatitis.
- Trial name
- NCT07336940
- Testing
- ENV-294 Capsule
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Enveda Therapeutics